Novo Nordisk: Strong Yield Masks Execution Risk as Oral Wegovy Becomes Linchpin

What happened

Novo Nordisk A/S remains a compelling yield play with >4% dividend yield and strong free cash flow, but the DeepValue master report reveals a more precarious underlying reality: the company has lost GLP-1 volume share and faces sustained US net-price compression. Oral semaglutide (Wegovy Pill), launched in 1Q26, reached ~33% of total Wegovy prescriptions by May 2026, yet the critical question is whether it expands the patient pool or merely cannibalizes injectables at a lower $149/month cash-pay price point. Meanwhile, Cigna's decision to drop GLP-1 obesity coverage for its own employees effective July 1, 2026, signals broader payer tightening that could accelerate net-price declines. At a 10.9x P/E and 9.3x EV/EBITDA, the stock already discounts substantial erosion, but upside depends on oral Wegovy sustaining prescription growth and demonstrating durable refill rates. The investment case hinges on observable proof points over the next 6–12 months, including ex-US launches and payer coverage decisions.

Implication

Over a 6–12 month horizon, the thesis will be validated or refuted by three factors: (1) oral Wegovy's mix stays at or above 33% of total Wegovy scripts while total prescriptions grow, (2) no additional large employer/payer coverage removals beyond Cigna, and (3) successful ex-US launches in 2H26. If these conditions hold, upside to $50–$60 is possible; if oral Wegovy stalls or payer tightening broadens, downside to $38 is probable. Position sizing should reflect this binary outcome.

Thesis delta

The master report shifts the narrative from a steady-growth yield story to a high-stakes execution play. The positive article's emphasis on FCF and dividend ignores the structural competitive and pricing headwinds that have already reset the stock's valuation. The critical new lens is that oral Wegovy is not just a volume driver but a pricing anchor: its $149 cash-pay price sets a ceiling for net prices across the franchise, and its adoption must outpace cannibalization to support earnings growth.